Diet-Induced Obesity Tumor Models for Cancer Studies

June 14, 2023

Diet-Induced Obesity Tumor Models for Cancer Studies

Obesity is a growing health concern worldwide. According to research, it is associated with an increased risk for cancer of at least 13 anatomic sites, including endometrial, esophageal, renal and pancreatic adenocarcinomas; hepatocellular carcinoma; gastric cardia cancer; meningioma; multiple myeloma; colorectal, postmenopausal breast, ovarian, gallbladder and thyroid cancers. Although the mechanism of this relationship is unclear, the existence of diet-based therapies (ketotherapy) as a form of cancer treatment suggests that diet somehow affects the activities of cancer cells or its environment. Preclinical studies are underway to gain a better understanding of how excess body weight affects the tumor microenvironment (TME) or how it impacts antitumor immunity.

Radiopharmaceutical Dosing Under FDA’s New Spotlight: What You Should Know

The FDA has issued a new draft guidance titled “Oncology Therapeutic Radiopharmaceuticals: Dosage Optimization During Clinical Development.” This ...

Read more +

Expanding Access to CART Therapies: TD2 Oncology Featured in SCRS inFocus

In June 2025, the FDA announced a major shift in regulatory guidance: the elimination of Risk Evaluation and Mitigation Strategy (REMS) requirements ...

Read more +

The Rise of Humanized Mouse Models in Oncology: What Drug Developers Need to Know

Traditional mouse models remain a cornerstone of preclinical oncology research. Syngeneic and xenografts mouse models continue to play a critical ...

Read more +

Get Started

Contact Us Today!

If you’re looking for an expert team to guide your trial with efficiency in mind, we can help. As the creators of the Dynamic Trial, TD2 provides start-to-finish support with trial strategy, design and execution for faster go-to-market potential.